UK's Astrazeneca buying US Biotech firm Alexion for 39 Billion dollars to expand in immunology

British pharmaceuticals group AstraZeneca, which is finalising a vaccine against Covid-19, said Saturday it was buying US biotech firm Alexion for $39 billion to boost its work on immunology.

"Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases,"...